AZTA

SEC source: 0000950170-24-029238 · ownership.xml · nonDerivative · entry 3

Joseph Jason · CIK 0001485448 · SVP, General Counsel, Secy.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,006

F1 · shares: The sales reported on this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2023.

SEC source: 0000950170-24-029238 · ownership.xml · nonDerivative · entry 2

Joseph Jason · CIK 0001485448 · SVP, General Counsel, Secy.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 102,006

F1 · shares: The sales reported on this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2023.

F2 · price: Represents the weighted average price for the shares purchased. The shares were purchased at per-share prices ranging from $65.00 to $65.39. The reporting person will provide to the SEC, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0000950170-24-029238 · ownership.xml · nonDerivative · entry 1

Joseph Jason · CIK 0001485448 · SVP, General Counsel, Secy.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 106,006

F1 · shares: The sales reported on this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2023.

F2 · price: Represents the weighted average price for the shares purchased. The shares were purchased at per-share prices ranging from $65.00 to $65.39. The reporting person will provide to the SEC, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0000950170-24-014561 · ownership.xml · nonDerivative · entry 1

Davis Robyn C · CIK 0001580601 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,587

F1 · shares: Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares.

SEC source: 0000950170-24-014560 · ownership.xml · nonDerivative · entry 1

Rosenblatt Michael · CIK 0001478797 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,042

F1 · shares: Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares.

SEC source: 0000950170-24-014564 · ownership.xml · nonDerivative · entry 1

Madaus Martin D · CIK 0001310268 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,465

F1 · shares: Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares.

SEC source: 0000950170-24-014565 · ownership.xml · nonDerivative · entry 1

Bousa Edward Peter · CIK 0001452605 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,465

F1 · shares: Grant of unrestricted shares under the company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares.

SEC source: 0000950170-24-014559 · ownership.xml · nonDerivative · entry 1

McLaughlin Erica · CIK 0001740348 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,818

F1 · shares: Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares.

SEC source: 0000950170-24-014563 · ownership.xml · nonDerivative · entry 1

HIRSCH DIDIER · CIK 0001226464 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,465

F1 · shares: Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares.

SEC source: 0000950170-24-014558 · ownership.xml · nonDerivative · entry 1

Nova Tina Susan · CIK 0001302605 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,069

F1 · shares: Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares.

SEC source: 0000950170-24-014562 · ownership.xml · nonDerivative · entry 1

Casal Frank · CIK 0001891819 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,392

F1 · shares: Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares.

SEC source: 0000950170-24-010489 · ownership.xml · nonDerivative · entry 1

Zhou Ginger · CIK 0001953934 · SVP and General Manager, Genom

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,942

F1 · shares: Purchase by Reporting Person under the Azenta, Inc. 2017 Employee Stock Purchase Plan. The purchase of shares was exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act") pursuant to Rule 16b-3(c) under the Exchange Act

SEC source: 0000950170-24-010487 · ownership.xml · nonDerivative · entry 1

Vacha Robin · CIK 0001832620 · SVP, GM Life Science Products

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,287

F1 · shares: Purchase by Reporting Person under the Azenta, Inc. 2017 Employee Stock Purchase Plan. The purchase of shares was exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act") pursuant to Rule 16b-3(c) under the Exchange Act

SEC source: 0000950170-24-009788 · ownership.xml · nonDerivative · entry 1

Hughes Violetta · CIK 0001991429 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,746

F1 · shares: The sale of shares by the reporting person to satisfy the reporting person's obligations with respect to withholding taxes in connection with the vesting on January 31, 2024 of 895 restricted stock units held by the reporting person.

SEC source: 0000950170-24-089938 · ownership.xml · nonDerivative · entry 1

Zhou Ginger · CIK 0001953934 · SVP and General Manager, Genom

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,006

F1 · shares: Purchase by Reporting Person under the Azenta, Inc. 2017 Employee Stock Purchase Plan. The purchase of shares was exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act") pursuant to Rule 16b-3(c) under the Exchange Act

SEC source: 0000950170-24-089937 · ownership.xml · nonDerivative · entry 1

Vacha Robin · CIK 0001832620 · SVP, GM Life Science Products

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,438

F1 · shares: Purchase by Reporting Person under the Azenta, Inc. 2017 Employee Stock Purchase Plan. The purchase of shares was exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act") pursuant to Rule 16b-3(c) under the Exchange Act

SEC source: 0001209191-23-057596 · doc4.xml · nonDerivative · entry 1

Vacha Robin · CIK 0001832620 · SVP, GM Life Science Products

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,788

SEC source: 0001209191-23-057389 · doc4.xml · nonDerivative · entry 1

Wang David Dong · CIK 0002000563 · SVP & GM, SMS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,478

F1 · shares: The sale of shares by the reporting person to satisfy the reporting person's obligations with respect to withholding taxes in connection with the vesting on December 2, 2023 of 470 restricted stock units held by the reporting person.

SEC source: 0001209191-23-056032 · doc4.xml · nonDerivative · entry 1

Gray David C · CIK 0001454514 · Chief Strategy & New Business

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,868

F1 · price: Represents the weighted average price for the shares sold. The shares were sold at per-share prices ranging from $54.43 to $55.06. The reporting person will provide to the SEC, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001209191-23-055706 · doc4.xml · nonDerivative · entry 2

Cueto Herman · CIK 0001997198 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,890

F2 · shares: Grant of restricted stock units to the Reporting Person under the Company's Long Term Incentive Plan. No amount was paid upon grant of the units. The units are subject to time-based vesting and will vest 50% per year, beginning on October 16, 2024.

SEC source: 0001209191-23-055706 · doc4.xml · nonDerivative · entry 1

Cueto Herman · CIK 0001997198 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,727

F1 · shares: Grant of restricted stock units to the Reporting Person under the Company's Long Term Incentive Plan. No amount was paid upon grant of the units. The units are subject to time-based vesting and will vest 33-1/3% per year, beginning on November 15, 2024.

SEC source: 0001209191-23-055732 · doc4.xml · nonDerivative · entry 3

Zhou Ginger · CIK 0001953934 · SVP and General Manager, Genom

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,494

F3 · shares: Grant of restricted stock units to the Reporting Person under the Company's Long Term Incentive Plan. No amount was paid upon grant of the units. The units are subject to time-based vesting and will vest 33-1/3% per year, beginning on November 15, 2024.

SEC source: 0001209191-23-055732 · doc4.xml · nonDerivative · entry 2

Zhou Ginger · CIK 0001953934 · SVP and General Manager, Genom

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,287

F2 · shares: The sale of shares by the reporting person to satisfy the reporting person's obligations with respect to withholding taxes in connection with the vesting on November 15, 2023 of 877 performance stock units and 970 of restricted stock units held by the reporting person.

SEC source: 0001209191-23-055724 · doc4.xml · nonDerivative · entry 3

Vacha Robin · CIK 0001832620 · SVP, GM Life Science Products

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,963

F3 · shares: Grant of restricted stock units to the Reporting Person under the Company's Long Term Incentive Plan. No amount was paid upon grant of the units. The units are subject to time-based vesting and will vest 33-1/3% per year, beginning on November 15, 2024.

SEC source: 0001209191-23-055724 · doc4.xml · nonDerivative · entry 2

Vacha Robin · CIK 0001832620 · SVP, GM Life Science Products

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,381

F2 · shares: The sale of shares by the reporting person to satisfy the reporting person's obligations with respect to withholding taxes in connection with the vesting on November 15, 2023 of 4,107 performance stock units and 2,755 of restricted stock units held by the reporting person.

SEC source: 0001209191-23-055727 · doc4.xml · nonDerivative · entry 1

Wang David Dong · CIK 0002000563 · SVP & GM, SMS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,616

F1 · shares: Grant of restricted stock units to the Reporting Person under the Company's Long Term Incentive Plan. No amount was paid upon grant of the units. The units are subject to time-based vesting and will vest 33-1/3% per year, beginning on November 15, 2024.

SEC source: 0001209191-23-055722 · doc4.xml · nonDerivative · entry 3

SCHWARTZ STEPHEN S · CIK 0001247436 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 446,536

F3 · shares: Grant of restricted stock units to the Reporting Person under the Company's Long Term Incentive Plan. No amount was paid upon grant of the units. The units are subject to time-based vesting and will vest 33-1/3% per year, beginning on November 15, 2024.

SEC source: 0001209191-23-055722 · doc4.xml · nonDerivative · entry 2

SCHWARTZ STEPHEN S · CIK 0001247436 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 424,088

F2 · shares: The sale of shares by the reporting person to satisfy the reporting person's obligations with respect to withholding taxes in connection with the vesting on November 15, 2023 of 16,426 performance stock units and 12,495 of restricted stock units held by the reporting person.

SEC source: 0001209191-23-055719 · doc4.xml · nonDerivative · entry 2

Robertson Lindon G · CIK 0001525267 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,081

F2 · shares: The sale of shares by the reporting person to satisfy the reporting person's obligations with respect to withholding taxes in connection with the vesting on November 15, 2023 of 6,297 performance stock units and 4,445 of restricted stock units held by the reporting person.

SEC source: 0001209191-23-055716 · doc4.xml · nonDerivative · entry 1

Pirogova Olga · CIK 0002000496 · SVP and CHRO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,207

F1 · shares: Grant of restricted stock units to the Reporting Person under the Company's Long Term Incentive Plan. No amount was paid upon grant of the units. The units are subject to time-based vesting and will vest 33-1/3% per year, beginning on November 15, 2024.

SEC source: 0001209191-23-055714 · doc4.xml · nonDerivative · entry 3

Joseph Jason · CIK 0001485448 · SVP, General Counsel, Secy.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,006

F3 · shares: Grant of restricted stock units to the Reporting Person under the Company's Long Term Incentive Plan. No amount was paid upon grant of the units. The units are subject to time-based vesting and will vest 33-1/3% per year, beginning on November 15, 2024.

SEC source: 0001209191-23-055714 · doc4.xml · nonDerivative · entry 2

Joseph Jason · CIK 0001485448 · SVP, General Counsel, Secy.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,508

F2 · shares: The sale of shares by the reporting person to satisfy the reporting person's obligations with respect to withholding taxes in connection with the vesting on November 15, 2023 of 3,559 performance stock units and 2,596 of restricted stock units held by the reporting person.

SEC source: 0001209191-23-055711 · doc4.xml · nonDerivative · entry 1

Hughes Violetta · CIK 0001991429 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,057

F1 · shares: Grant of restricted stock units to the Reporting Person under the Company's Long Term Incentive Plan. No amount was paid upon grant of the units. The units are subject to time-based vesting and will vest 33-1/3% per year, beginning on November 15, 2024.

SEC source: 0001209191-23-055709 · doc4.xml · nonDerivative · entry 3

Gray David C · CIK 0001454514 · Chief Strategy & New Business

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,047

F3 · shares: Grant of restricted stock units to the Reporting Person under the Company's Long Term Incentive Plan. No amount was paid upon grant of the units. The units are subject to time-based vesting and will vest 33-1/3% per year, beginning on November 15, 2024.

SEC source: 0001209191-23-055709 · doc4.xml · nonDerivative · entry 2

Gray David C · CIK 0001454514 · Chief Strategy & New Business

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,756

F2 · shares: The sale of shares by the reporting person to satisfy the reporting person's obligations with respect to withholding taxes in connection with the vesting on November 15, 2023 of 2,875 performance stock units and 2,161 of restricted stock units held by the reporting person.

SEC source: 0001209191-23-055732 · doc4.xml · nonDerivative · entry 1

Zhou Ginger · CIK 0001953934 · SVP and General Manager, Genom

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,745

F1 · shares: Represents shares issued upon the vesting of performance-based units granted on November 13, 2020, of which one-third was determined to be earned at 150% and converted into restricted stock units which vested on November 15, 2023. No amount was paid by the reporting person upon grant or vesting of the performance-based units.

SEC source: 0001209191-23-055724 · doc4.xml · nonDerivative · entry 1

Vacha Robin · CIK 0001832620 · SVP, GM Life Science Products

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,327

F1 · shares: Represents shares issued upon the vesting of performance-based units granted on November 13, 2020, of which one-third was determined to be earned at 150% and converted into restricted stock units which vested on November 15, 2023. No amount was paid by the reporting person upon grant or vesting of the performance-based units.

SEC source: 0001209191-23-055722 · doc4.xml · nonDerivative · entry 1

SCHWARTZ STEPHEN S · CIK 0001247436 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 436,953

F1 · shares: Represents shares issued upon the vesting of performance-based units granted on November 13, 2020, of which one-third was determined to be earned at 150% and converted into restricted stock units which vested on November 15, 2023. No amount was paid by the reporting person upon grant or vesting of the performance-based units.

SEC source: 0001209191-23-055719 · doc4.xml · nonDerivative · entry 1

Robertson Lindon G · CIK 0001525267 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,860

F1 · shares: Represents shares issued upon the vesting of performance-based units granted on November 13, 2020, of which one-third was determined to be earned at 150% and converted into restricted stock units which vested on November 15, 2023. No amount was paid by the reporting person upon grant or vesting of the performance-based units.

SEC source: 0001209191-23-055714 · doc4.xml · nonDerivative · entry 1

Joseph Jason · CIK 0001485448 · SVP, General Counsel, Secy.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,339

F1 · shares: Represents shares issued upon the vesting of performance-based units granted on November 13, 2020, of which one-third was determined to be earned at 150% and converted into restricted stock units which vested on November 15, 2023. No amount was paid by the reporting person upon grant or vesting of the performance-based units.

SEC source: 0001209191-23-055709 · doc4.xml · nonDerivative · entry 1

Gray David C · CIK 0001454514 · Chief Strategy & New Business

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,917

F1 · shares: Represents shares issued upon the vesting of performance-based units granted on November 13, 2020, of which one-third was determined to be earned at 150% and converted into restricted stock units which vested on November 15, 2023. No amount was paid by the reporting person upon grant or vesting of the performance-based units.

SEC source: 0001209191-23-045613 · doc4.xml · nonDerivative · entry 2

Gray David C · CIK 0001454514 · Chief Strategy & New Business

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,042

F2 · price: Represents the weighted average price for shares sold on August 11, 2023 at a range between $55.92 to $56.20. The reporting person will provide to the Securities and Exchange Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001209191-23-045827 · doc4a.xml · nonDerivative · entry 2

Gray David C · CIK 0001454514 · Chief Strategy & New Business

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,610

F3 · price: Represents the weighted average price for shares sold on August 11, 2023 at a range between $55.92 to $56.20. The reporting person will provide to the Securities and Exchange Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001209191-23-045615 · doc4.xml · nonDerivative · entry 1

Vacha Robin · CIK 0001832620 · SVP, GM Life Science Products

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,220

F1 · price: Represents the weighted average price for shares sold on August 10, 2023 at a range between $55.00 and $55.01. The reporting person will provide to the Securities and Exchange Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001209191-23-045613 · doc4.xml · nonDerivative · entry 1

Gray David C · CIK 0001454514 · Chief Strategy & New Business

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,919

F1 · price: Represents the weighted average price for shares sold on August 10, 2023 at a range between $55.20 to $57.66. The reporting person will provide to the Securities and Exchange Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001209191-23-045827 · doc4a.xml · nonDerivative · entry 1

Gray David C · CIK 0001454514 · Chief Strategy & New Business

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,487

F1 · shares: On August 14, 2023, the reporting person filed a Form 4 which understated the number of shares sold by the reporting person on August 10, 2023 by 6,421 shares. The correct number of shares sold by the reporting person was 10,732.

F2 · price: Represents the weighted average price for shares sold on August 10, 2023 at a range between $55.20 to $57.66. The reporting person will provide to the Securities and Exchange Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001209191-23-045166 · doc4.xml · nonDerivative · entry 1

Zane Ellen M · CIK 0001369850 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,134

F1 · price: The sales reported on this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2022.

SEC source: 0001209191-23-043948 · doc4.xml · nonDerivative · entry 1

Vacha Robin · CIK 0001832620 · SVP, GM Life Science Products

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,620

F1 · shares: Purchase by Reporting Person under the Azenta, Inc. 2017 Employee Stock Purchase Plan. The purchase of shares was exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act") pursuant to Rule 16b-3(c) under the Exchange Act

SEC source: 0001209191-23-043947 · doc4.xml · nonDerivative · entry 1

Zhou Ginger · CIK 0001953934 · SVP and General Manager, Genom

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,868

F1 · shares: Purchase by Reporting Person under the Azenta, Inc. 2017 Employee Stock Purchase Plan. The purchase of shares was exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act") pursuant to Rule 16b-3(c) under the Exchange Act

SEC source: 0001209191-23-043946 · doc4.xml · nonDerivative · entry 1

Robertson Lindon G · CIK 0001525267 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,563

F1 · shares: Purchase by Reporting Person under the Azenta, Inc. 2017 Employee Stock Purchase Plan. The purchase of shares was exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act") pursuant to Rule 16b-3(c) under the Exchange Act.